Publications by authors named "Dacoregio M"
Background: Trastuzumab deruxtecan (T-DXd) has shown promising activity in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC) and central nervous system (CNS) involvement. In this updated meta-analysis, we explore the effectiveness of T-DXd in a large subset of patients with HER2-positive BC and CNS disease.
Methods: A systematic search was made on September 16th, 2024, for studies investigating T-DXd in the scenario of HER2-positive BC and brain metastases (BMs) and/or leptomeningeal disease (LMD).
Article Synopsis
- Sacituzumab Govitecan (SG) has shown significant clinical benefits for breast cancer patients but is associated with considerable toxicity.
- A meta-analysis of seven studies included 928 patients on SG and highlighted high rates of adverse events, particularly neutropenia (70%) and grade ≥3 neutropenia (46%).
- The findings suggest a need for careful monitoring and management of side effects when using SG, as it poses a higher risk of neutropenia, diarrhea, and anemia compared to standard treatment options.
Article Synopsis
- Recent advancements in antibody-drug conjugates (ADCs) have improved outcomes for patients with HER2-low-expressing breast cancer, a group that previously lacked effective targeted therapies.
- A systematic review and meta-analysis was conducted to evaluate the effectiveness of various ADCs, including trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG), in treating HER2-low advanced or metastatic breast cancer, pulling data from multiple reputable sources.
- The findings revealed that patients treated with T-DXd had significantly better outcomes in terms of objective response rate, disease control rate, and overall survival compared to those receiving traditional treatment options, highlighting the potential of ADCs as effective therapies.
Immunotherapy Plus Chemotherapy Versus Chemotherapy Alone as First-Line Treatment for Advanced Urothelial Cancer: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Clin Genitourin Cancer
October 2024
Introduction: Platinum-based chemotherapy (CTX) has historically been the primary treatment for advanced urothelial cancer (aUC), with limited alternative options. The therapeutic landscape experienced a paradigm shift following the results of the EV-302 and Checkmate-901 trials, which led to the approval of Enfortumab vedotin plus pembrolizumab (EV-P) as the preferred first-line treatment, and nivolumab plus CTX for those unable to receive the preferred regimen. Currently, further investigations are underway to explore PD-1 and PD-L1 inhibitors in the initial treatment of aUC.
View Article and Find Full Text PDFArticle Synopsis
- There is no standard treatment for patients with locally advanced head and neck squamous cell carcinoma (LA HNSCC) who cannot tolerate cisplatin-based therapies, prompting a systematic review for alternative options.
- The review analyzed 24 studies involving 4,450 patients, finding that cetuximab combined with radiotherapy was the most common treatment, followed by carboplatin with radiotherapy, showing varied median overall survival rates.
- The findings suggest a need for diverse treatment combinations and emphasize the necessity for more clinical studies to explore effective options for this patient group.
Objectives: Li-Fraumeni syndrome (LFS) is a cancer syndrome associated with early-onset neoplasias. The use of whole-body magnetic resonance imaging (WBMRI) is recommended for regular cancer screening, however, evidence supporting the benefits in asymptomatic LFS patients is limited. This study aims to assess the clinical utility of WBMRI in germline TP53 mutation carriers at baseline and follow-up.
View Article and Find Full Text PDFArticle Synopsis
- A systematic review and meta-analysis were conducted to evaluate the effectiveness of retreating advanced non-small-cell lung cancer (NSCLC) patients with EGFR-tyrosine kinase inhibitors (TKIs), analyzing 19 studies with a total of 886 patients.
- The pooled results indicated a median overall survival (OS) of 11.7 months and a progression-free survival (PFS) of 3.2 months, with an overall response rate (ORR) of 15% and disease control rate (DCR) of 61%.
- While the analysis highlighted the benefits of EGFR-TKI retreatment, especially with 3rd generation TKIs, it faced limitations due to heterogeneity in data and the inability to conduct certain
Background: Trastuzumab deruxtecan (T-DXd) has shown promising results in patients with breast cancer brain metastases (BCBMs). We conducted a systematic review and meta-analysis to evaluate the effectiveness and safety of T-DXd in the human epidermal growth factor receptor 2 (HER2)-positive BCBM population.
Patients And Methods: We searched PubMed, Embase, and Cochrane Library databases as well as American Society of Clinical Oncology (ASCO), European Society for Medical Oncology (ESMO), and San Antonio Breast Cancer Symposium (SABCS) websites for clinical trials (CTs) and observational studies evaluating T-DXd in patients with HER2-positive BCBM.
Background: Alzheimer's disease (AD) has several risk factors. is the main one, and it has been suggested that there may be a synergy between it and as a risk factor.
Objective: To investigate the association between and as a risk factor for AD.
Cancer is associated with significant morbimortality globally. Advances in screening, diagnosis, management and survivorship were substantial in the last decades, however, challenges in providing personalized and data-oriented care remain. Artificial intelligence (AI), a branch of computer science used for predictions and automation, has emerged as potential solution to improve the healthcare journey and to promote precision in healthcare.
View Article and Find Full Text PDF